<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02815059</url>
  </required_header>
  <id_info>
    <org_study_id>HCI85188</org_study_id>
    <nct_id>NCT02815059</nct_id>
  </id_info>
  <brief_title>Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone</brief_title>
  <official_title>A Phase 1 Study of Combining Ibrutinib, Dasatinib and Prednisone in Patients 60 Years or Older With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, single-center, open label, prospective, single-arm, dose-escalation and&#xD;
      multi-dose study evaluating the use of ibrutinib in combination with dasatinib and prednisone&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Termination of Investigator Initiated Studies using Ibrutinib&#xD;
  </why_stopped>
  <start_date type="Actual">September 28, 2016</start_date>
  <completion_date type="Actual">January 9, 2018</completion_date>
  <primary_completion_date type="Actual">January 9, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events of combination of ibrutinib and dasatinib</measure>
    <time_frame>Patient safety will be evaluated throughout the treatment period (treatment with Ibrutinib and dasatinib which is expected to last 90 days for each patient)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Ibrutinib, Dasatinib and prednisone, all patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Ibrutinib 420mg PO daily (dose level 0) or 560mg PO daily (dose level +1) administered Day 15 through day 90.</description>
    <arm_group_label>Ibrutinib, Dasatinib and prednisone, all patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Dasatinib 100mg PO daily (Day 1 through Day 90). Dasatinib dose will be increased to 140mg daily in patients tolerating dasatinib 100mg who have not achieved a complete bone marrow response (less than 5% blasts) by Day 22 or who have not achieved major molecular response by Day 43.</description>
    <arm_group_label>Ibrutinib, Dasatinib and prednisone, all patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 60mg/m2 PO daily (Day 1 through Day 32)</description>
    <arm_group_label>Ibrutinib, Dasatinib and prednisone, all patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed new diagnosis of Philadelphia chromosome-positive or BCR-ABL1 positive&#xD;
             precursor B cell acute lymphoblastic leukemia (B-ALL) based on ≥ 20% lymphoblasts in&#xD;
             bone marrow or blood. Outside specimens will be subject to central review at the HCI&#xD;
             (Huntsman Cancer Institute) Department of Pathology. BCR-ABL1 or&#xD;
             Philadelphia-chromosome positivity may be determined by RT-PCR, conventional&#xD;
             cytogenetics and/or FISH.&#xD;
&#xD;
          -  Men and woman ≥ 50 years of age&#xD;
&#xD;
          -  ECOG status 0 - 2&#xD;
&#xD;
          -  Biochemical values as defined by the protocol.&#xD;
&#xD;
          -  Women of childbearing potential and men who are sexually active must be practicing a&#xD;
             highly effective method of birth control during and after the study consistent with&#xD;
             local regulations regarding the use of birth control methods for subjects&#xD;
             participating in clinical trials. Men must agree to not donate sperm during and after&#xD;
             the study. For women, these restrictions apply for 1 month after the last dose of&#xD;
             study drug. For men, these restrictions apply for 3 months after the last dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum (beta-human chorionic&#xD;
             gonadotropin [β-hCG]) or urine pregnancy test at screening within 7 days of&#xD;
             enrollment.&#xD;
&#xD;
          -  Able to provide informed consent and willing to sign an approved consent form that&#xD;
             conforms to federal and institutional guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major surgery or a wound that has not fully healed within 4 weeks of enrollment.&#xD;
&#xD;
          -  Prior exposure to dasatinib (&gt;7 days), Bruton's tyrosine kinase inhibitor exposure, or&#xD;
             prior chemotherapy for ALL (up to 7 days of steroids are allowed)&#xD;
&#xD;
          -  History of stroke or intracranial hemorrhage within 6 months prior to enrollment.&#xD;
&#xD;
          -  Grade ≥ 2 QTc prolongation on screening ECG within 28 days of enrollment, or history&#xD;
             of ventricular arrhythmia.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease such as uncontrolled or symptomatic&#xD;
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of&#xD;
             screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by&#xD;
             the New York Heart Association Functional Classification.&#xD;
&#xD;
          -  Hepatic impairment (Child Pugh Classes A- C) that is not considered to be the result&#xD;
             of leukemic involvement as determined by the PI&#xD;
&#xD;
          -  Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg,&#xD;
             phenprocoumon).&#xD;
&#xD;
          -  Requires chronic treatment with strong CYP3A inhibitors.&#xD;
&#xD;
          -  Vaccinated with live, attenuated vaccines within 4 weeks of enrollment.&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or&#xD;
             active Hepatitis B Virus infection or any uncontrolled active systemic infection.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Herbal preparations or over-the-counter supplements containing herbal ingredients (St.&#xD;
             John's Wort, Estroven, Blue Cohosh) are prohibited during treatment and must be&#xD;
             stopped within 24h of first dose of ibrutinib.&#xD;
&#xD;
          -  Any life-threatening illness, medical condition, or organ system dysfunction which, in&#xD;
             the investigator's opinion, could compromise the subject's safety, interfere with the&#xD;
             absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue&#xD;
             risk.&#xD;
&#xD;
          -  Known central nervous system lymphoma (does not include diagnosis of ALL with CNS&#xD;
             involvement)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>June 21, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

